Testing cognitive normal for Alzheimer's disease prediction

Abstract

One standing challenge for Alzheimer's disease (AD) research is early diagnosis, which provides a time window for early intervention. Sharmin et al recently reported a positive association between plasma ptau181 and plasma metabolites, medium‐ and long‐chain acylcarnitines (ACs) in both cognitively normal (CN) Aβ− and CN Aβ+ older adults, suggesting a link between initial Aβ pathology and acylcarnitine‐mediated energy metabolism pathways. Consistently, ACs could classify PET‐Aβ status in elderly individuals. This study has provided further clues for early biomarker searching for AD, linking metabolic pathways with AD pathogenesis.image